Physician profile
Jeffrey A Smith
NPI 1629017785
$14,837.94
in general payments reported to CMS, 2019-2025
52 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $1,849 · 2021: $2,362 · 2022: $2,129 · 2023: $2,133 · 2024: $2,714 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,048 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,048.06 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,607.78 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $1,302.70 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,291.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,242.64 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,233.65 | 2021-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $790.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $786.92 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $520.58 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $440.16 | 2019-2025 | Trintellix |
| Allergan, INC. | $406.56 | 2019-2020 | |
| Glaxosmithkline, LLC. | $406.23 | 2019-2025 | Nucala, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.41 | 2019-2023 | Synjardy, Jardiance |
| Novo Nordisk INC | $383.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $309.36 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Lundbeck LLC | $302.50 | 2020-2025 | Rexulti, Vyepti |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.